MethylGene opts out of HDAC neurodegenerative collaboration with EnVivo

February 6, 2008 - MethylGene Inc. (TSX:MYG) and EnVivo Pharmaceuticals announced that MethylGene has exercised its right to opt-out of further funding in its collaboration with EnVivo signed in February 2005. EnVivo will continue to research and develop histone deacetylase (HDAC) inhibitors for neurodegenerative disorders such as Huntington's, Alzheimer's and Parkinson's diseases under license from MethylGene. A lead compound has been identified during the collaboration and designated as a clinical candidate by EnVivo. MethylGene will receive royalties on net sales of any approved product as well as a share of any sublicense income from future partnerships EnVivo may enter into with other companies for neurodegenerative programs... MethylGene's Press Release- EnVivo's Press Release-

Forest Laboratories, Positive Results of Memantine Study of Once-Daily Formulation

Feb. 5, 2008 - Forest Laboratories, Inc. (NYSE: FRX) announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda(R), a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor... Forest Laboratories' Press Release-

Neuro-Hitech, Cognitive Improvement From Phase Two Clinical Trial of Huperzine A In Alzheimer's Disease Patients

Feb 06, 2008 - Neuro-Hitech, Inc. (NASDAQ: NHPI), a New York-based biopharmaceutical company focused on developing innovative drugs for the treatment of neurodegenerative diseases, announced top-line results from the double-blind part of a phase 2 clinical trial of Huperzine A in mild to moderate Alzheimer’s disease (AD) patients... Neuro-Hitech's press Release-